Shuttle Pharmaceuticals Holdings, Inc.
NCM: SHPHLive Quote
📈 ZcoreAI Score
Our AI model analyzes Shuttle Pharmaceuticals Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SHPH Z-Score →About Shuttle Pharmaceuticals Holdings, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
📊 Fundamental Analysis
Shuttle Pharmaceuticals Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -791.0%, which indicates that capital utilization is currently under pressure.
At a current price of $0.70, SHPH currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $0.50 - $11.25).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$3.91M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
0.72
52W High
$11.25
52W Low
$0.50
Avg Volume
2.55M
Day High
Day Low